Award details

Pre-clinical development of a simian adenovirus vectored respiratory syncytial virus (RSV) vaccine

ReferenceBBS/E/I/00001632
Principal Investigator / Supervisor Dr Geraldine Taylor
Co-Investigators /
Co-Supervisors
Institution The Pirbright Institute
DepartmentThe Pirbright Institute Department
Funding typeResearch
Value (£) 73,315
StatusCurrent
TypeInstitute Project
Start date 01/08/2012
End date 31/07/2015
Duration36 months

Abstract

There is no commercial vaccine against RSV, a major cause of respiratory disease in infants and the elderly. A safe and effective RSV vaccine is needed that will not only protect young children, but which will also boost immunity in the elderly. We have constructed several AdCh/RSV vaccine candidates expressing RSV F, N and M2-1 proteins, which induce complete protection against RSV infection in BALB/c mice and cotton rats, either alone or in a heterologous prime/boost vaccine strategy with MVA/RSV. Importantly, intranasal vaccination did not prime for enhanced pulmonary pathology in either mice or cotton rats, following RSV challenge. However, a transient weight loss was observed in mice. Given the history of RSV vaccine-augmented disease in infants, further studies including ones in a more relevant animal model are required prior to embarking on clinical trials. The primary objectives of the project are to: (i) optimise and further evaluate AdCh/RSV vaccine candidates and the AdCh-RSV/MVA-RSV in mice and cotton rats (ii) evaluate the protective efficacy of the novel AdCh/RSV vaccine in calves, a natural infection model of RSV (iii) generate pre-GMP material for a rapid implementation of clinical development

Summary

unavailable
Committee Not funded via Committee
Research TopicsImmunology, Microbiology, Pharmaceuticals
Research PriorityX – Research Priority information not available
Research Initiative X - not in an Initiative
Funding SchemeX – not Funded via a specific Funding Scheme
terms and conditions of use (opens in new window)
export PDF file